providing special products to special people

• Home
• About Us
  • Corporate Strategy
  • Organization
  • Management
    • Experience
  • Supervisory Board
  • Investors
• Products
  • Dantrium^® / Dantrolen^®
  • Savene^®
  • MuGard™
  • Xerotin^®
• Business Development
  • Partnerships
• Careers
• Press Room
• Contacts
• Legal Disclaimer

• 04/03/2010

  SpePharm announces the acquisition of Savene from TopoTarget,

• 20/04/2009

  SpePharm announces the European launches of two new products: MuGard^® and Xerotin^®

• 14/04/2009

  SpePharm announces a claim in excess of €35 M against BioAlliance Pharma for breaking up their Joint-Venture SpeBio

Information on
Dantrium / Dantrolen »
Informationen zu
Dantrium / Dantrolen »
Informaciones sobre
Dantrium / Dantrolen »
A propos du
Dantrium / Dantrolène »
Informazioni su
Dantrium / Dantrolen »

14 April 2009

SpePharm announces a claim in excess of €35 M against BioAlliance Pharma for breaking up their Joint-Venture SpeBio

SpePharm Holding BV announces it intends to file a claim for financial damages and losses of not less than 35 Million Euros against BioAlliance Pharma SA, a French company listed on Paris Euronext.

« Back